Victory Capital Management Inc. Has $377.67 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Victory Capital Management Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2,628.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,675,479 shares of the medical research company’s stock after purchasing an additional 1,614,063 shares during the period. Victory Capital Management Inc.’s holdings in IQVIA were worth $377,670,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of IQV. Claret Asset Management Corp lifted its stake in shares of IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. lifted its stake in shares of IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after acquiring an additional 60 shares during the last quarter. Private Advisor Group LLC lifted its stake in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the last quarter. Finally, Brookstone Capital Management lifted its stake in shares of IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $181.10 on Friday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a 50-day moving average price of $173.56 and a two-hundred day moving average price of $193.68. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04. The company has a market cap of $30.23 billion, a P/E ratio of 22.44, a PEG ratio of 1.55 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the business posted $2.70 EPS. The business’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Morgan Stanley set a $225.00 price objective on IQVIA in a report on Thursday, May 7th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Mizuho set a $215.00 price objective on IQVIA in a report on Monday, February 23rd. Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Finally, Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.